Company profile: Janux Therapeutics
1.1 - Company Overview
Company description
- Provider of immunotherapies that activate T cells in the tumor microenvironment while sparing healthy tissue, including PSMA-TRACTr (JANX007) for metastatic castration-resistant prostate cancer and EGFR-TRACTr (JANX008) in Phase 1 for carcinomas, built on proprietary TRACTr and TRACIr bispecific platforms; partnered with Merck to develop next-generation T cell engager immunotherapies.
Products and services
- TRACTr and TRACIr platforms: Proprietary framework engineers bispecific molecules that activate T cells in the tumor microenvironment to generate anti-tumor immune responses while sparing healthy tissue
- PSMA-TRACTr (JANX007): Tumor-activated T cell engager targets PSMA to treat metastatic castration-resistant prostate cancer, aiming to elicit anti-tumor immunity without affecting a patient’s healthy tissue
- EGFR-TRACTr (JANX008): Phase 1 T cell engager targets EGFR for various carcinomas, activating anti-tumor immune responses while designed to avoid impact on healthy tissue
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Janux Therapeutics
FogPharma
HQ: United States
Website
- Description: Provider of precision medicines based on Helicons, a new class combining antibody-like targeting with broad tissue distribution and intracellular target engagement of small molecules; pipeline includes FOG-001, a first-in-class TCF-blocking β-catenin inhibitor (Phase 1/2), β-catenin and ERG degraders, an ERG/DNA binding inhibitor (discovery), and Helicon-enabled alpha radioligand therapies (hit identification).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full FogPharma company profile →
PMV Pharma
HQ: United States
Website
- Description: Provider of p53-targeted small molecule therapeutics for cancer, including the investigational candidate rezatapopt (PC14586) designed to reactivate the p53 Y220C mutation for advanced solid tumors. Offers drug discovery focused on restoring mutant p53 tumor suppressor function and conducts clinical trials to assess safety and efficacy in patients with specific p53 mutations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PMV Pharma company profile →
Pulse Biosciences
HQ: United States
Website
- Description: Provider of medical devices using Nanosecond Pulsed Field Ablation (nsPFA), including the CellFX System for various therapeutic areas including cardiology; the CellFX nsPFA 360 Cardiac Catheter for atrial fibrillation pulmonary vein isolation; the CellFX nsPFA Cardiac Clamp for surgical cardiac ablation; and a percutaneous electrode for non-cardiac, nonthermal ablation of cellular tissue while sparing noncellular structures.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pulse Biosciences company profile →
Lymphatica Medtech
HQ: Switzerland
Website
- Description: Provider of medical device development, creating a minimally invasive solution for chronic lymphedema.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lymphatica Medtech company profile →
TheraPharm
HQ: Germany
Website
- Description: Provider of monoclonal antibody-based diagnostic and therapeutic biotechnology solutions in hematology, specializing in research, development, and manufacturing for targeted radiation of hematopoietic malignant and non-malignant diseases and lymphoproliferative diseases, conditioning for allogeneic stem cells, and diagnostics of inflammatory diseases and bone marrow metastases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TheraPharm company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Janux Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Janux Therapeutics
2.2 - Growth funds investing in similar companies to Janux Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Janux Therapeutics
4.2 - Public trading comparable groups for Janux Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →